Patients and caregivers can check whether a medicine they rely on still has an unfinished study that the Food and Drug Administration required after approval. The agency's postmarket requirements and commitments database is free to search by product name. Its current data run through July 31, 2026, and the FDA says it updates the listings quarterly, in January, April, July, and October.
The search is simple, but the results are easy to misread. A "delayed" label is not a finding that a drug is unsafe, and a "pending" label can describe a study that has not enrolled a single patient. For a parent whose child takes a rare-disease drug, knowing the difference can shape the questions asked at the next appointment.
Update Note: This article explains how patients can read the FDA's public records on required follow-up studies, following MedicalDaily's earlier coverage of a KFF Health News analysis of delayed studies. (Latest verified data: FDA database updated July 31, 2026; next quarterly update expected in October 2026, according to the FDA.)
MedicalDaily previously reported that nearly 600 FDA-required drug and biologic studies were behind schedule, based on a KFF Health News analysis of August data. That figure covers drugs and biologics only. KFF found "dozens" more device studies running behind.
Seven Status Labels and the Company Reports Behind Them
The FDA's status definitions sort every listed study into one of seven categories. "Pending" means no subjects have been enrolled, but the study is not yet behind schedule. "Ongoing" means it is on or ahead of its original timetable. "Delayed" means it has fallen behind at any stage, including enrollment, analysis, or the final report.
The remaining labels describe how a study ends. "Terminated" means the company stopped early and has not filed a final report. "Submitted" means a final report is in, but the FDA has not yet responded in writing. "Fulfilled" means the FDA is satisfied, and "Released" means the FDA excused the company because the study was no longer feasible or useful.
The source of the information matters. According to the FDA's frequently asked questions page, the listings draw on agency letters and on annual status reports filed by the companies themselves. The FDA makes the final call only on whether a study is fulfilled or released.
A filter labeled "Required Under" shows why a study exists. Options include accelerated approval, where a confirmatory trial must verify a real benefit; the Pediatric Research Equity Act, which covers studies in children; and section 505(o)(3), the FDA's authority to require safety studies.
Three Drug Entries and a Delayed Ankle Implant
KFF Health News quoted entries that show what a search can reveal. For Pfizer's COVID-19 pill Paxlovid, a pregnancy safety study was due by the end of 2024. "The trial completion and final report milestones were missed," the database said.
For Sarepta's Duchenne muscular dystrophy drug Exondys 51, approved in 2016, a final report was due in May 2021. The entry explained, "The final report milestone was missed because the sponsor requested milestone extensions due to study delays." For the opioid Oxaydo, the database said the FDA "issued a failure to respond letter" in 2022. The product was discontinued in 2023.
Medical devices sit in separate systems. The FDA's Post-Approval Studies database covers higher-risk devices and uses its own labels, including "Progress Adequate" and "Delayed." As of Oct. 2, it listed two studies of DJO Global's S.T.A.R. ankle replacement system as delayed. KFF reported that the main study, approved in 2009, aimed for at least 500 patients but enrolled 142.
An HHS spokesperson, Emily Hilliard, told KFF Health News that a delay "should not be treated as evidence that a product has an unresolved safety or effectiveness issue." Sanket Dhruva, a cardiologist and associate professor of medicine at the University of California, San Francisco, saw a different risk. "Doctors rely on this evidence, patients rely on this evidence, and if that evidence is not there, it's going to lead to a lot of uncertainty," he told the outlet.
Penalties on the Books and the Record of Using Them
The FDA has legal tools for studies that slip. Under its guidance on section 505(o)(3), missing a required timetable without good cause, as the FDA defines it, is a violation. A drug can then be deemed misbranded, and civil penalties can reach $250,000 per violation, rising to as much as $10 million in a single proceeding if violations continue after notice.
The FAQ page adds that failing to file a required annual report "will be considered a violation" and "could result in enforcement action." For accelerated approval drugs, Congress added expedited withdrawal procedures in late 2022. The FDA's accelerated approval guidance lists failure to run a confirmatory trial "with due diligence" as one ground for withdrawal.
The tools exist, but public evidence of their use is thin. The FDA withdrew the cancer drug Pepaxto in February 2024 after its confirmatory study failed to confirm benefit. Neither KFF's report nor the HHS response cited a count of penalties tied to late studies; Hilliard said only that the FDA uses its powers "where appropriate." The FDA's proposal to withdraw the vasculitis drug Tavneos remains pending, and Amgen has requested a hearing that has not been publicly scheduled.
Using the Results Without Stopping a Prescription
A search is quick and free. Enter the brand name, note the status label and its explanation, and check the "Required Under" field. For an implanted device, search the device database by manufacturer. Saving the entry makes it easier to discuss with a prescriber or pharmacist.
A delayed label alone is not a reason to stop treatment. Patients should not stop or change a prescribed medicine without speaking with a health care professional. A clinician can explain whether the missing data matter for a patient's age, pregnancy or condition.
People who suspect a side effect can report it to the FDA's MedWatch program. The next quarterly database update is expected in October, and the Tavneos hearing remains the most closely watched test of the FDA's withdrawal process.
The database cannot say whether a medicine is right for one person. It does show which promised studies are on time, which are late, and which never started, information worth bringing into an exam room.
Key Questions Answered
Where can I check whether my medicine has an unfinished FDA-required study?
The FDA's postmarket requirements and commitments database is free and searchable by product name, company or application number. Implanted and higher-risk devices are tracked in separate FDA device databases.
Does a "delayed" study mean my drug is unsafe?
No. HHS says a delay should not be treated as evidence of an unresolved safety or effectiveness problem. It means the study is behind its original schedule, which can still leave gaps in what doctors know.
Who reports a study's status?
Most status information comes from annual reports filed by the companies, along with FDA letters. The FDA decides when a study is fulfilled or released.
What can the FDA do when a company misses a deadline?
The FDA can deem a drug misbranded and seek civil penalties of up to $250,000 per violation, with higher amounts for continuing violations. For accelerated approval drugs, it can use expedited procedures to withdraw approval.
Should I stop my medicine if its study is late?
Do not stop or change a prescribed medicine without talking with a health care professional. Bring the database entry to your prescriber or pharmacist and ask whether the missing data apply to you.
When will the database be updated next?
The FDA says it updates the data quarterly, in January, April, July, and October. The current listings reflect data through July 31, 2026.
Published by Medicaldaily.com
